{"pmid":32502594,"title":"Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.","text":["Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.","BACKGROUND: Emerging evidence shows that severe COVID-19 can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and venous thromboembolism (VTE). This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. METHODS: A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase and Cochrane Controlled Register of Trials were systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. RESULTS: The systematic review and critical analysis of the literature based on13 PICO questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. CONCLUSIONS: The evidence on the optimal strategies to prevent, diagnose, and treat venous thromboembolism in patients with COVID-19 is sparse, but rapidly evolving.","Chest","Moores, Lisa K","Tritschler, Tobias","Brosnahan, Shari","Carrier, Marc","Collen, Jacob F","Doerschug, Kevin","Holley, Aaron B","Jimenez, David","LeGal, Gregoire","Rali, Parth","Wells, Philip","32502594"],"abstract":["BACKGROUND: Emerging evidence shows that severe COVID-19 can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and venous thromboembolism (VTE). This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. METHODS: A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase and Cochrane Controlled Register of Trials were systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. RESULTS: The systematic review and critical analysis of the literature based on13 PICO questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. CONCLUSIONS: The evidence on the optimal strategies to prevent, diagnose, and treat venous thromboembolism in patients with COVID-19 is sparse, but rapidly evolving."],"journal":"Chest","authors":["Moores, Lisa K","Tritschler, Tobias","Brosnahan, Shari","Carrier, Marc","Collen, Jacob F","Doerschug, Kevin","Holley, Aaron B","Jimenez, David","LeGal, Gregoire","Rali, Parth","Wells, Philip"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502594","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.chest.2020.05.559","keywords":["covid-19","dic","deep vein thrombosis","hypercoagulability","pulmonary embolism","venous thromboembolism"],"locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1668804508871819264,"score":9.490897,"similar":[{"pmid":32361152,"title":"The Use of Bronchoscopy during the COVID-19 Pandemic: CHEST/AABIP Guideline and Expert Panel Report.","text":["The Use of Bronchoscopy during the COVID-19 Pandemic: CHEST/AABIP Guideline and Expert Panel Report.","BACKGROUND: The coronavirus disease 2019 (COVID-19) has swept the globe and is causing significant morbidity and mortality. Given that the virus is transmitted via droplets, open airway procedures such as bronchoscopy pose a significant risk to health care workers (HCW). The goal of this guideline was to examine the current evidence on the role of bronchoscopy during the COVID-19 pandemic and the optimal protection of patients and HCW. METHODS: A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed specific topics on bronchoscopy related to COVID-19 infection and transmission. MEDLINE (via PubMed) was systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to assess the quality of studies and to grade the level of evidence to support each recommendation. When evidence did not exist, suggestions were developed based on consensus using the modified Delphi process RESULTS: The systematic review and critical analysis of the literature based on six PICO questions resulted in six statements: one evidence-based graded recommendation and 5 ungraded consensus-based statements. CONCLUSIONS: The evidence on the role of bronchoscopy during the COVID-19 pandemic is sparse. To maximize protection of patients and HCW, bronchoscopy should be used sparingly in the evaluation and management of patients with suspected or confirmed COVID-19 infections. In an area where community transmission of COVID-19 infection is present, bronchoscopy should be deferred for non-urgent indications and, if necessary to perform, HCW should wear personal protective equipment while performing the procedure even on asymptomatic patients.","Chest","Wahidi, Momen M","Shojaee, Samira","Lamb, Carla R","Ost, David","Maldonado, Fabien","Eapen, George","Caroff, Daniel A","Stevens, Michael P","Ouellette, Daniel R","Lilly, Craig","Gardner, Donna D","Glisinski, Kristen","Pennington, Kelly","Alalawi, Raed","32361152"],"abstract":["BACKGROUND: The coronavirus disease 2019 (COVID-19) has swept the globe and is causing significant morbidity and mortality. Given that the virus is transmitted via droplets, open airway procedures such as bronchoscopy pose a significant risk to health care workers (HCW). The goal of this guideline was to examine the current evidence on the role of bronchoscopy during the COVID-19 pandemic and the optimal protection of patients and HCW. METHODS: A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed specific topics on bronchoscopy related to COVID-19 infection and transmission. MEDLINE (via PubMed) was systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to assess the quality of studies and to grade the level of evidence to support each recommendation. When evidence did not exist, suggestions were developed based on consensus using the modified Delphi process RESULTS: The systematic review and critical analysis of the literature based on six PICO questions resulted in six statements: one evidence-based graded recommendation and 5 ungraded consensus-based statements. CONCLUSIONS: The evidence on the role of bronchoscopy during the COVID-19 pandemic is sparse. To maximize protection of patients and HCW, bronchoscopy should be used sparingly in the evaluation and management of patients with suspected or confirmed COVID-19 infections. In an area where community transmission of COVID-19 infection is present, bronchoscopy should be deferred for non-urgent indications and, if necessary to perform, HCW should wear personal protective equipment while performing the procedure even on asymptomatic patients."],"journal":"Chest","authors":["Wahidi, Momen M","Shojaee, Samira","Lamb, Carla R","Ost, David","Maldonado, Fabien","Eapen, George","Caroff, Daniel A","Stevens, Michael P","Ouellette, Daniel R","Lilly, Craig","Gardner, Donna D","Glisinski, Kristen","Pennington, Kelly","Alalawi, Raed"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361152","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.chest.2020.04.036","keywords":["bronchoscopy","covid-19"],"topics":["Prevention"],"weight":1,"_version_":1666138495565955073,"score":615.8079},{"pmid":32423903,"title":"Thrombotic risk in COVID-19: a case series and case-control study.","text":["Thrombotic risk in COVID-19: a case series and case-control study.","BACKGROUND: A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous thromboembolism (VTE) are extremely limited. METHODS: We describe three cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an inpatient cohort, and a case-control study to identify risk factors associated with VTE. RESULTS: We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were seen in confirmed VTE cases (4.1 vs 1.2 mug/mL, P<0.001). CONCLUSION: Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be beneficial in guiding management.","Clin Med (Lond)","Stoneham, Simon M","Milne, Kate M","Nuttal, Elisabeth","Frew, Georgina H","Sturrock, Beattie R","Sivaloganathan, Helena","Ladikou, Eleni E","Drage, Stephen","Phillips, Barbara","Chevassut, Timothy Jt","Eziefula, Alice C","32423903"],"abstract":["BACKGROUND: A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous thromboembolism (VTE) are extremely limited. METHODS: We describe three cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an inpatient cohort, and a case-control study to identify risk factors associated with VTE. RESULTS: We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were seen in confirmed VTE cases (4.1 vs 1.2 mug/mL, P<0.001). CONCLUSION: Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be beneficial in guiding management."],"journal":"Clin Med (Lond)","authors":["Stoneham, Simon M","Milne, Kate M","Nuttal, Elisabeth","Frew, Georgina H","Sturrock, Beattie R","Sivaloganathan, Helena","Ladikou, Eleni E","Drage, Stephen","Phillips, Barbara","Chevassut, Timothy Jt","Eziefula, Alice C"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423903","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.7861/clinmed.2020-0228","keywords":["covid-19","d-dimer","deep vein thrombosis","pulmonary embolism","venous thromboembolism"],"locations":["heparin"],"e_drugs":["Heparin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667252837900353536,"score":386.0512},{"pmid":32451823,"title":"Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.","text":["Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.","Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 microg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level >/= 1.0 microg/ml and >/= 3 microg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 mug/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.","J Thromb Thrombolysis","Artifoni, Mathieu","Danic, Gwenvael","Gautier, Giovanni","Gicquel, Pascal","Boutoille, David","Raffi, Francois","Neel, Antoine","Lecomte, Raphael","32451823"],"abstract":["Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 microg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level >/= 1.0 microg/ml and >/= 3 microg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 mug/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies."],"journal":"J Thromb Thrombolysis","authors":["Artifoni, Mathieu","Danic, Gwenvael","Gautier, Giovanni","Gicquel, Pascal","Boutoille, David","Raffi, Francois","Neel, Antoine","Lecomte, Raphael"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451823","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s11239-020-02146-z","keywords":["covid-19","d-dimer","pulmonary embolism","venous thromboembolism"],"locations":["French","thromboprophylaxis","thromboprophylaxis","heparin","thromboprophylaxis"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["Heparin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667881798549372928,"score":366.00784},{"pmid":32320517,"title":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.","text":["High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.","BACKGROUND: Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated severe COVID-19 patients. OBJECTIVES: Systematic assessment of VTE using complete duplex ultrasound (CDU) in anticoagulated COVID-19 patients. PATIENTS AND METHODS: We performed a retrospective study in 2 French intensive care units (ICU) were CDU is performed as a standard of care. A CDU from thigh to ankle at selected sites with Doppler waveforms and images was performed early during ICU stay in patients admitted with COVID-19. Anticoagulation dose was left to the discretion of the treating physician based on the individual risk of thrombosis. Patients were classified as treated with prophylactic anticoagulation or therapeutic anticoagulation. Pulmonary embolism was systematically searched in patients with persistent hypoxemia or secondary deterioration. RESULTS: From March 19(th) to April 11(th) of 2020, 26 consecutive patients with severe COVID-19 were screened for VTE. 8 patients (31%) were treated with prophylactic anticoagulation whereas 18 patients (69%) were treated with therapeutic anticoagulation. The overall rate of VTE in patients was 69%. The proportion of VTE was significantly higher in patients treated with prophylactic anticoagulation when compared to the other group (100% vs. 56%, respectively, p=0.03). Surprisingly, we found a high rate of thromboembolic events in COVID-19 patients treated with therapeutic anticoagulation, with 56% of VTE and 6 pulmonary embolisms. CONCLUSION: Our results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID-19 patients.","J Thromb Haemost","Llitjos, Jean-Francois","Leclerc, Maxime","Chochois, Camille","Monsallier, Jean-Michel","Ramakers, Michel","Auvray, Malika","Merouani, Karim","32320517"],"abstract":["BACKGROUND: Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated severe COVID-19 patients. OBJECTIVES: Systematic assessment of VTE using complete duplex ultrasound (CDU) in anticoagulated COVID-19 patients. PATIENTS AND METHODS: We performed a retrospective study in 2 French intensive care units (ICU) were CDU is performed as a standard of care. A CDU from thigh to ankle at selected sites with Doppler waveforms and images was performed early during ICU stay in patients admitted with COVID-19. Anticoagulation dose was left to the discretion of the treating physician based on the individual risk of thrombosis. Patients were classified as treated with prophylactic anticoagulation or therapeutic anticoagulation. Pulmonary embolism was systematically searched in patients with persistent hypoxemia or secondary deterioration. RESULTS: From March 19(th) to April 11(th) of 2020, 26 consecutive patients with severe COVID-19 were screened for VTE. 8 patients (31%) were treated with prophylactic anticoagulation whereas 18 patients (69%) were treated with therapeutic anticoagulation. The overall rate of VTE in patients was 69%. The proportion of VTE was significantly higher in patients treated with prophylactic anticoagulation when compared to the other group (100% vs. 56%, respectively, p=0.03). Surprisingly, we found a high rate of thromboembolic events in COVID-19 patients treated with therapeutic anticoagulation, with 56% of VTE and 6 pulmonary embolisms. CONCLUSION: Our results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID-19 patients."],"journal":"J Thromb Haemost","authors":["Llitjos, Jean-Francois","Leclerc, Maxime","Chochois, Camille","Monsallier, Jean-Michel","Ramakers, Michel","Auvray, Malika","Merouani, Karim"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320517","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14869","keywords":["covid-19","sars-cov-2","anticoagulation","critical care","pulmonary embolism","venous thromboembolism"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment"],"weight":1,"_version_":1666138493731995648,"score":358.45547},{"pmid":32396903,"title":"Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?","text":["Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?","Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease.","Acta Haematol","Tal, Shir","Spectre, Galia","Kornowski, Ran","Perl, Leor","32396903"],"abstract":["Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease."],"journal":"Acta Haematol","authors":["Tal, Shir","Spectre, Galia","Kornowski, Ran","Perl, Leor"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396903","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1159/000508233","keywords":["covid-19","deep vein thrombosis","pulmonary emboli","venous thromboembolism"],"topics":["Treatment"],"weight":1,"_version_":1666627827809648640,"score":350.0937}]}